Kyverna Therapeutics Appoints Warner Biddle as CEO and Adds Christi Shaw to Board of Directors

Kyverna Therapeutics, a leading biopharmaceutical company specializing in cell therapies for autoimmune diseases, has made significant leadership changes.
Warner Biddle Named CEO and Board Member
Warner Biddle, a renowned figure with over 30 years of experience in commercial and franchise leadership, has been appointed as the Chief Executive Officer of Kyverna Therapeutics. His track record includes successful launches of CAR T therapies in hematology.
Christi Shaw Joins the Board
In another strategic move, Christi Shaw, a seasoned executive in the life sciences field, has been appointed to the Board of Directors at Kyverna Therapeutics. Her vast experience across therapeutic areas adds significant value to the company's leadership team.
A New Chapter Begins
These appointments mark a pivotal moment for Kyverna Therapeutics as it strengthens its position as a pioneer in cell therapy. With a focus on clinical development, manufacturing, and commercialization, the company is poised for growth and innovation in the autoimmune disease space. Mr. Biddle, the newly appointed CEO, expressed his enthusiasm for joining Kyverna at a crucial stage of its development. He emphasized the potential of CAR T therapeutics to revolutionize the treatment of autoimmune diseases and bring new hope to millions of patients. Ms. Shaw's addition to the Board further solidifies the company's strategic vision and commitment to advancing healthcare solutions.
Inducement Grant
To mark Mr. Biddle's appointment, Kyverna granted him an inducement option to purchase shares of its common stock. This gesture underscores the company's confidence in its new CEO and sets the stage for future growth and success.
About Kyverna Therapeutics
Kyverna Therapeutics is dedicated to developing innovative cell therapies for autoimmune diseases, with a focus on CAR T-cell therapy. The company's pipeline includes cutting-edge treatments for a range of conditions, offering new possibilities for patients in need.
Forward-Looking Statements
As Kyverna Therapeutics embarks on this new chapter, the company remains committed to its mission of advancing healthcare through groundbreaking therapies. The leadership changes signal a period of growth and transformation, setting the stage for exciting developments in the field of autoimmune disease treatment.